New myosin inhibitors reshape treatment of obstructive hypertrophic cardiomyopathy
A new review maps how mavacamten and aficamten are reshaping the treatment pathway for hypertrophic obstructive cardiomyopathy, from first-line drugs ...
A new review maps how mavacamten and aficamten are reshaping the treatment pathway for hypertrophic obstructive cardiomyopathy, from first-line drugs ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.